COVID-19 And Cell And Gene Sector: Contingency Planning For 2021 And Beyond

By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

COVID-19 has impacted the cell and gene industry in more ways than you may realize. In fact, every aspect of the sector — from the research lab to the regulatory landscape to QA and more — has been affected, perhaps irreversibly. But that’s not necessarily bad news. To learn what SMEs in the cell and gene space have encountered as a result of COVID-19, I talked to some of the brightest luminaries representing the sector’s various subsets by asking each of them the same question:

As a result of COVID-19, how have you and your team had to pivot to ensure continued success in 2021 and beyond?